

SPECIALTY GUIDELINE MANAGEMENT

TECENTRIQ (atezolizumab)

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

A. FDA-Approved Indications

1. Locally advanced or metastatic urothelial carcinoma
Tecentriq is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who:
 - a. Are not eligible for cisplatin-containing chemotherapy, or
 - b. Have disease progression during or following any platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant chemotherapy
2. Metastatic non-small cell lung cancer (NSCLC)
Tecentriq is indicated for the treatment of patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Tecentriq

All other indications are considered experimental/investigational and are not a covered benefit.

II. CRITERIA FOR INITIAL APPROVAL

A. Urothelial carcinoma

Authorization of 12 months may be granted for treatment of locally advanced or metastatic urothelial carcinoma when either of the following criteria is met:

1. Member is not eligible for cisplatin-containing chemotherapy
2. The disease has progressed during or following platinum-containing chemotherapy

B. Non-small cell lung cancer (NSCLC)

Authorization of 12 months may be granted for treatment of metastatic NSCLC when both of the following criteria are met:

1. The disease has progressed during or following platinum-containing chemotherapy
2. Members with positive epidermal growth factor receptor (EGFR) mutation or positive anaplastic lymphoma kinase (ALK) gene arrangement have had disease progression on FDA-approved therapy for these aberrations (e.g., erlotinib, afatinib, gefitinib, crizotinib, ceritinib) for these mutations prior to receiving Tecentriq

III. CONTINUATION OF THERAPY

Tecentriq SGM P2017

CVS Caremark is an independent company that provides pharmacy benefit management services to CareFirst BlueCross BlueShield and CareFirst BlueChoice, Inc. members.

CareFirst BlueCross BlueShield is the shared business name of CareFirst of Maryland, Inc. and Group Hospitalization and Medical Services, Inc. CareFirst of Maryland, Inc., Group Hospitalization and Medical Services, Inc., CareFirst BlueChoice, Inc., The Dental Network and First Care, Inc. are independent licensees of the Blue Cross and Blue Shield Association. In the District of Columbia and Maryland, CareFirst MedPlus is the business name of First Care, Inc. In Virginia, CareFirst MedPlus is the business name of First Care, Inc. of Maryland (used in VA by: First Care, Inc.). © Registered trademark of the Blue Cross and Blue Shield Association

All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

IV. REFERENCE

1. Tecentriq [package insert]. South San Francisco, CA: Genentech, Inc.; April 2017.